Browse by category

The FDA has approved Eli Lilly and Company’s Foundayo (orforglipron) for adults with obesity or overweight with weight-related medical problems.  Foundayo is a once-daily small molecule (non-peptide) oral glucagon-like peptide-1 receptor agonist (GLP-1ra) that can be taken any time of the day without restrictions on food and water intake. "People living with obesity need treatment options that meet them where they are – and for many, a once-daily pill that can be taken with n

Researchers in France have identified a significant shift in the country towards more complex and potentially more morbid types of revisional metabolic bariatric surgeries (RMBS), underscoring the need of careful patient selection through preoperative assessment and personalised postoperative management to reduce risks and optimise outcomes in this population. The aim of their observational study was to assess the rate of RMBS in France and to outline the associated complicati

Scientists at City of Hope and TGen (part of City of Hope) have explained a major mechanism for why gaining excess weight increases the risk of cancer across multiple organs. The findings emphasise the importance of maintaining a healthy weight from early childhood and propose a potentially more accurate way than body mass index (BMI) to predict the increase in cancer risk associated with obesity. "People have long been told that obesity increases cancer risk, but they are ra

The preliminary findings from a multi-centre study assessing magnetic gastroileostomy bipartition (MagGI procedure) as a revisional option for suboptimal sleeve gastrectomy (SG), suggest that SG-revisional MagGI was technically feasible and achieved promising excess weight loss of 66.0%. Self-aligning GT Metabolic MagDI System magnets fused together The study was conducted in adults (body mass index [BMI, kg/m2] ≥30.0–≤50.0). The 90-day primary feasibility endpoint was magnet

For patients undergoing body contouring surgery to remove excess abdominal skin after significant weight loss, use of GLP-1 weight-loss medications may have mixed effects on complication risks, according to a study by researchers from West Virginia University School of Medicine, Morgantown, WV. Share of all patients who take a GLP-1 RA by state. Credit: Plastic & Reconstructive Surgery (2025). DOI: 10.1097/prs.0000000000012405 "As GLP-1 receptor agonist (GLP1ra) medications b

Dr Alexander Parr, a board-certified general and bariatric surgeon with the Broward Health Physician Group, has reached a milestone achievement, performing his 2,555th robotic-assisted procedure using the Da Vinci Surgical System at Broward Health Imperial Point, marking a significant landmark in his career and underscoring Broward Health’s commitment to advanced surgical technology. Alexander Parr “Reaching 2,555 robotic-assisted procedures is an exciting milestone, but more

The last participant has been randomised and dosed in Amylyx Pharmaceuticals’ pivotal Phase 3 LUCIDITY clinical trial of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist with an FDA Breakthrough Therapy Designation in post-bariatric hypoglycemia (PBH). LUCIDITY is a 16-week, multicentre, randomised, double-blind, placebo-controlled trial evaluating the efficacy and safety of avexitide in adults with PBH following Roux-en-Y gast

Both Roux-en-Y gastric bypass (RYGB) and single-anastomosis duodeno-ileal bypass (SADI-S) are effective and safe revisional options after sleeve gastrectomy (SG), according to researchers from Hamad Medical Corporation, Doha, Qatar. They noted that SADI-S offers superior long-term weight-loss and metabolic outcomes, whereas RYGB remains preferable for patients with significant or persistent GERD. “Tailoring revisional procedure selection to patient characteristics and ensurin

Researchers from Saudi Arabia have reported that although general awareness of obesity’s metabolic impact is high, understanding of the therapeutic role of metabolic bariatric surgery for T2DM remained limited. Despite that fact that injectable therapies were more frequently preferred than surgical options, their study did not find definitive conclusions regarding the underlying drivers of these preferences. “These findings highlight the need for structured public education i

Researchers from Northwestern Medicine at Northwestern University, Chicago, Ill, have discovered novel molecular mechanisms that contribute to recovery from diabetic kidney disease following bariatric surgery in adolescents with type 2 diabetes and obesity. These mechanisms may serve as potential targets for non-surgical treatments for diabetic kidney disease, according to a multi-institutional study co-authored by Dr Thomas Inge, the Lydia J Fredrickson Board Designated Prof